ClinicalTrials.gg
CompletedNCT07414056Updated Oct 1, 2026

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

An observational study in Acute Respiratory Distress Syndrome (ARDS), sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 1 Year to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Ain Shams University · Observational

How we know

Updated Oct 1, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
1 Year to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Respiratory Distress Syndrome with a site in Egypt — 11 open to participants now, 11 under way, 1 of them phase 3. Respiratory Distress Syndrome · Egypt.

Started
2025
with 4 others
Observational
9 of 32
6 open now
Registered
30th of 32
by date
Lead sponsor
7 of 32
Ain Shams University

Among the 32 studies in Respiratory Distress Syndrome with a site in Egypt, this one is one of 5 that started in 2025, is one of 9 observational ones, and was the 30th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

11 of the 32 studies in Respiratory Distress Syndrome with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 1 Year to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Respiratory Distress Syndrome with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.

Read the detailed description

The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.

  • A prospective observational cohort study will be performed in our burn ICU at Ain Shams University Hospitals. Ethical clearance will be taken from the institutional ethics committee. Written informed consent will be obtained from the patients/authorized representatives of the patients.
  • All eligible pediatric patients with severe burns will be enrolled within 24 hours of admission after obtaining informed consent.
  • Minimum sample needed for statistical significance was calculated a priori and found to be (60).
  • After consent, Patients' characteristics (age, sex, etc….), clinical parameters (TBSA, Abbreviated Burn Severity Index [ABSI], presence of inhalational injury), and comorbidities will be recorded.
  • Complete blood count (CBC) will be done upon admission and will be repeated on days 1, 3, 5 and 7.
  • Total leucocyte count (TLC), differential leucocyte count (DLC) and platelet count (PC) will be reported as part of the CBC results. NLR and PLR will be calculated as per the following: NLR: ratio of absolute neutrophil count to absolute lymphocyte count. PLR: ratio of platelet counts to absolute lymphocyte count.
  • Data about respiratory status at ICU admission (invasive or non-invasive mechanical ventilation, high-flow oxygen therapy) and progression to endotracheal intubation and invasive mechanical ventilation (IMV), the day of endotracheal intubation and IMV initiation, and duration of ventilation will be recorded.
  • Patients will be evaluated on days 0,1, 3, 5, 7 of admission for diagnosis of ARDS.
  • ARDS will be determined using the pediatric ARDS criteria from the Pediatric Acute Lung Injury Consensus Conference.

Primary outcome:

o To evaluate the predictive value of admission NLR and PLR for development of ARDS within 30 days in pediatric burn patients.

Secondary outcomes:

  • Determine optimal cut-off values (ROC) of NLR and PLR for ARDS prediction.
  • Compare predictive performance of NLR and PLR with established clinical predictors (TBSA%, inhalation injury, age).
  • Study the predictive value of the dynamic changes of NLR/PLR for mechanical ventilation need, ventilator days, ICU length of stay, and mortality.
03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
04

Who can participate

Ages eligible
1 Year to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A prospective observational cohort study will be performed in our burn ICU at Ain Shams University Hospitals. Ethical clearance will be taken from the institutional ethics committee. Written informed consent will be obtained from the patients/authorized representatives of the patients.

All eligible pediatric patients with severe burns will be enrolled within 24 hours of admission after obtaining informed consent.

Minimum sample needed for statistical significance was calculated a priori and found to be (60).

After consent, Patients' characteristics (age, sex, etc….), clinical parameters (TBSA, Abbreviated Burn Severity Index [ABSI], presence of inhalational injury), and comorbidities will be recorded.

Patients will be evaluated on days 0,1, 3, 5, 7 of admission for diagnosis of ARDS.

ARDS will be determined using the pediatric ARDS criteria from the Pediatric Acute Lung Injury Consensus Conference .

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1-12 years.
  • Patients presenting within 24 hours of burn injury.
  • Patients presenting with severe burns 20-40% of total body surface area (TBSA).
  • Thermal burns or scalds.
  • Both sexes.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate in the trial.
  • Age \<1 \& >12 years.
  • Delayed admission >24h post-injury.
  • Patients presenting with burns \<20% or >40% of TBSA.
  • Non-thermal burns.
  • Associated medical comorbidities: Chronic liver or kidney diseases, anemia.
  • Preexisting chronic lung disease (e.g., cystic fibrosis, severe bronchopulmonary dysplasia).
  • Inflammatory conditions (e.g., inflammatory bowel disease).
  • individuals, diseases, those undergoing treatment with immunosuppressants, , cytotoxic chemotherapy.
  • Known , hematologic malignancy or conditions altering WBC/ significantly.
  • Previous malnutrition.
  • Immunosuppressive therapy prior to admission (e.g., chronic steroids).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testNeutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios

    Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients

06

What researchers measure

Primary outcomes

  1. Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction using the Pediatric Index of Mortality 2 score (PIM2 score).

    the predictive value of admission Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction within 30 days in 60 pediatric burn patients using the Pediatric Index of Mortality 2 score (PIM2 score). The PIM2 score outputs a probability of death between 0% and 100%, the higher the score, the higher the motality risk. Low risk: \<5-10% predicted mortality; Moderate risk: 10-20%; High risk: \>20%

    Time frame: Within 30 days

Secondary outcomes

  1. optimal cut-off values

    optimal cut-off values (Receiver Operating Characteristic curve "ROC") of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction in 60 pediatric burn patients.

    Time frame: 30 days

  2. comparison between Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) in clinical aspects using pediatric risk of mortality score (PRISM III score)

    Compare predictive performance of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) with established clinical predictors (Total Body Surface Area Percentage "TBSA%", inhalation injury, age in years) in 60 pediatric burn patients using pediatric risk of mortality score (PRISM III score). PRISM III Score Ranges from 0 to \>25. 0-5 means Low risk of mortality, mild critical illness; 6-15 means Moderate risk; significant physiologic instability; 16-25 means High risk; severe multi-organ involvement; \>25 means Extremely high risk; very critical state.

    Time frame: 30 days

  3. Dynamic changes of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) using the Pediatric Logistic Organ Dysfunction (PELOD) score to assess severity of burn.

    Study the predictive value of the dynamic changes of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for mechanical ventilation need, ventilator days, ICU length of stay in days, and mortality in 60 pediatric burn patients using the Pediatric Logistic Organ Dysfunction (PELOD) score. Maximum score: 33. Higher scores indicate greater severity. Higher PELOD-2 scores and involvement of multiple organ systems correlate with increased risk of mortality. A score \>10 or involvement of \>2 organs indicates significantly elevated risk.

    Time frame: 30 days

07

Study locations

1 site
  • Ain Shams University
    Cairo, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Sep 2026, 10 months.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 10 months is below that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion May 2027 → Sep 2026 and completion Nov 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2026
First posted
Feb 17, 2026
StartActual
Nov 10, 2025
Primary completionActual
Sep 10, 2026was May 2027
CompletionActual
Sep 10, 2026was Nov 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 1, 2026
Primary completion
May 10, 2027→Sep 10, 2026 (actual)
Oct 1, 2026
Study completion
Nov 10, 2027→Sep 10, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Completed
    Primary completion May 10, 2027→Sep 10, 2026 (now actual)
    Study completion Nov 10, 2027→Sep 10, 2026 (now actual)
    + 2 other changes: site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07414056
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Nov 10, 2025
Primary completion
Sep 10, 2026
Completion
Sep 10, 2026
Last update
Oct 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion